Potpara Tatjana S, Polovina Marija M, Djikic Dijana, Marinkovic Jelena M, Kocev Nikola, Lip Gregory Y H
Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
PLoS One. 2014 Sep 3;9(9):e106439. doi: 10.1371/journal.pone.0106439. eCollection 2014.
Many blood biomarkers have a positive association with stroke outcome, but adding blood biomarkers to the National Institutes of Health Stroke Scale (NIHSS) did not significantly improve its discriminatory ability. We investigated the association of the CHA2DS2-VASc score with unfavourable functional outcome (defined as a 30-day modified Rankin Scale [mRS] ≥ 3) in patients presenting with acute ischemic stroke (AIS), and examined whether the addition of blood biomarkers (troponin I [TnI], fibrinogen, C-reactive protein [CRP]) affects the model discriminatory ability.
We conducted an observational single-centre study of consecutive patients with AIS. All patients were admitted to hospital within 24 hours from the neurological symptoms onset.
Of 240 patients (mean age 70.0 ± 8.9 years), unfavourable 30-day outcome occurred in 92 (38.3%). Patients with mRS ≥ 3 were older and more likely to have atrial fibrillation or other comorbidities (all p<0.001). They had higher levels of CRP, fibrinogen, TnI and higher CHA2DS2-VASc and CHADS2 scores (all p<0.05). The adjusted CHA2DS2-VASc score had excellent predictive ability for poor stroke outcome (c-statistic 0.982;95%CI,0.964-1.000, p<0.001). Whilst CRP had the highest sensitivity (83.7%), cardiac TnI was the most specific (97.3%) for prediction of poor stroke outcome (cut-off: >0.09 µg/L). Compared with each of these biomarkers, CHA2DS2-VASc score had significantly better predictive ability for poor stroke outcome (c-statistic for CRP, Fibrinogen and TnI was 0.853;95%CI,0.802-0.895, 0.848;95%CI,0.796-0.891, and 0.792;95%CI,0.736-0.842, all p<0.001, respectively, versus 0.932;95%CI,0.892-0.960, p<0.001 for the CHA2DS2-VASc, all p for the comparisons<0.01). There was no significant difference in the predictive ability of the CHA2DS2-VASc score vs. combinations of the CHA2DS2-VASc and TnI or TnI, fibrinogen and CRP (z statistic 0.369, p = 0.7119; integrated discrimination index 0.00801 and 0.00172, respectively, both p>0.05).
The CHA2DS2-VASc score alone reliably predicts 30-day unfavourable outcome of stroke. Adding blood biomarkers to the CHA2DS2-VASc score did not significantly increase the predictive ability of the model.
许多血液生物标志物与卒中预后呈正相关,但将血液生物标志物添加到美国国立卫生研究院卒中量表(NIHSS)中并未显著提高其鉴别能力。我们研究了急性缺血性卒中(AIS)患者的CHA2DS2-VASc评分与不良功能预后(定义为30天改良Rankin量表[mRS]≥3)之间的关联,并检验添加血液生物标志物(肌钙蛋白I [TnI]、纤维蛋白原、C反应蛋白[CRP])是否会影响模型的鉴别能力。
我们对连续的AIS患者进行了一项单中心观察性研究。所有患者在出现神经症状后24小时内入院。
240例患者(平均年龄70.0±8.9岁)中,92例(38.3%)出现了30天不良预后。mRS≥3的患者年龄更大,更有可能患有心房颤动或其他合并症(所有p<0.001)。他们的CRP、纤维蛋白原、TnI水平更高,CHA2DS2-VASc和CHADS2评分也更高(所有p<0.05)。调整后的CHA2DS2-VASc评分对不良卒中预后具有出色的预测能力(c统计量0.982;95%CI,0.964-1.000,p<0.001)。虽然CRP的敏感性最高(83.7%),但心脏TnI对不良卒中预后的预测特异性最强(97.3%)(临界值:>0.09μg/L)。与这些生物标志物中的每一种相比,CHA2DS2-VASc评分对不良卒中预后的预测能力明显更好(CRP、纤维蛋白原和TnI的c统计量分别为0.853;95%CI,0.802-0.895、0.848;95%CI,0.796-0.891和0.792;95%CI,0.736-0.842,所有p<0.001,而CHA2DS2-VASc的c统计量为0.932;95%CI,0.892-0.960,p<0.001,所有比较的p<0.01)。CHA2DS2-VASc评分与CHA2DS2-VASc和TnI或TnI、纤维蛋白原和CRP组合的预测能力无显著差异(z统计量0.369,p = 0.7119;综合鉴别指数分别为0.00801和0.00172,均p>0.05)。
单独的CHA2DS2-VASc评分可可靠地预测卒中30天不良预后。将血液生物标志物添加到CHA2DS2-VASc评分中并未显著提高模型的预测能力。